
Vtapa 1%30 gm
Synovia Pharma PLC
Tapinarof cream is a non-steroidal topical medicine used for the following skin conditions: Established / Approved Uses Plaque psoriasis (adults): Topical treatment of plaque psoriasis in adult…
Tapinarof cream is a non-steroidal topical medicine used for the following skin conditions:
Tapinarof is not approved for use in children below 2 years of age or for plaque psoriasis in the pediatric population, as safety and efficacy have not been established for these uses.
The dose and frequency of Tapinarof cream depend on the indication being treated. Always follow the physician's specific instructions.
| Indication | Age group | Recommended dosing |
|---|---|---|
| Plaque psoriasis | Adults | Apply a thin layer of Tapinarof cream once daily to the affected skin areas. |
| Atopic dermatitis | Adults and children ≥2 years | Apply a thin layer of Tapinarof cream once daily to the affected skin areas. |
Treatment should generally be limited to the affected (lesional) skin areas only, and Tapinarof should be discontinued once control is achieved unless the physician advises otherwise. Improvement is usually assessed over 8-12 weeks of continuous use; if there is no improvement within this period, the physician should be consulted.
The side-effect profile of Tapinarof differs somewhat by indication.
| Indication | Common side effects (≥1%) |
|---|---|
| Plaque psoriasis | Folliculitis (most common, ~20%), nasopharyngitis, contact dermatitis, headache, pruritus (itching), influenza-like illness. |
| Atopic dermatitis | Upper respiratory tract infection, folliculitis, lower respiratory tract infection, headache, asthma exacerbation, vomiting, ear infection, limb pain, abdominal pain. |
Folliculitis (inflammation of hair follicles) is the most frequently reported local skin reaction with Tapinarof and is usually mild to moderate and self-limiting, though it occasionally requires stopping treatment. Contact dermatitis, application-site irritation, and, rarely, urticaria (hives) or other hypersensitivity reactions can also occur. If a severe or worsening skin reaction, or signs of an allergic reaction, develop while using Tapinarof, treatment should be stopped and a physician consulted promptly.
Tapinarof is contraindicated in patients with known hypersensitivity to Tapinarof or to any other component of the cream formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.